Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
We adjust the dose if needed
Knowing this, it is easy to understand why people who are diagnosed with obesity can benefit from GLP-1 medications
This limit was not derived from a toxicity signal at higher frequencies but rather from the design of the RECONNECT trials, where the mean number of doses used per month was approximately 2.5, 3
She is hopeful that staying active, eating well, and possibly taking a cheaper medication will help her keep the weight loss she was so stunned to achieve
Dosing: Daily subcutaneous injection Maximum dose: 3.0 mg/day Average weight loss (SCALE trial): 8% over 56 weeks List price: ~$1,349/mo FDA-approved for: Adults and adolescents 12+ with BMI 30 (or 27 with comorbidities) Zepbound (Tirzepatide) The 2023 Newcomer Zepbound, FDA-approved in November 2023, contains tirzepatide a dual GIP/GLP-1 receptor agonist
